How early should you engage a CDMO?

How early should you engage a CDMO? is a pharma and life sciences industry update from BioPharma Dive. The story may affect commercial strategy, market access planning, stakeholder engagement, competitive positioning, and near-term monitoring for pharmaceutical and biotech teams.

Kevin Kane, CMC Sciences Director, Clinical Research, Thermo Fisher Scientific · 2026-10-19

Discover which CMC activities can move forward early, and which decisions need to remain flexible.

Source: BioPharma Dive